Anzeige
Erschienen in:
01.12.2007 | Retinal disorders
Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 12/2007
Einloggen, um Zugang zu erhaltenAbstract
Background
To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in the treatment of subretinal neovascularization (SRNV) secondary to type 2A idiopathic juxtafoveal telangiectasia (IJT).
Methods
Intravitreal bevacizumab (1.25 mg/0.05 ml) was injected as primary treatment into six eyes of six patients with SRNV due to IJT in this nonrandomized, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) findings were examined before and after treatment. The patients were followed up for 3–6 months.
Results
Pre-injection BCVA measured 20/400 to 20/120 (mean 20/200). After a mean follow-up of 4.2 months, post-injection BCVA measured 20/200 to 20/50 (mean 20/100). At last visit BCVA improved two or more lines in five eyes (83%) and remained the same in one eye (17%). The mean central foveal thickness improved from 263 μm (range, 165 to 393 μm) to 201 μm (range, 126 to 351 μm), representing an average reduction of 62 μm. Only one eye received more than one (2) bevacizumab injections. No significant complications were observed.
Conclusions
In this small series, intravitreal bevacizumab appears to be a safe and effective treatment for SRNV secondary to type 2A IJT.